Immutep Limited (ASX:IMM)
0.2500
-0.0100 (-3.85%)
Sep 16, 2025, 4:10 PM AEST
Immutep Revenue
In the fiscal year ending June 30, 2025, Immutep had annual revenue of 5.04M AUD with 31.28% growth. Immutep had revenue of 1.90M in the half year ending June 30, 2025, with 4.17% growth.
Revenue
5.04M
Revenue Growth
+31.28%
P/S Ratio
72.76
Revenue / Employee
162.70K
Employees
31
Market Cap
366.97M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 5.04M | 1.20M | 31.28% |
Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 23.73B |
Pro Medicus | 212.98M |
Cochlear | 2.34B |
Sonic Healthcare | 9.65B |
Ramsay Health Care | 17.79B |
Ansell | 3.06B |
Telix Pharmaceuticals | 1.01B |
Mesoblast | 26.23M |
Immutep News
- 8 days ago - Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewsWire
- 6 weeks ago - Immutep Quarterly Activities Report Q4 FY25 - GlobeNewsWire
- 7 weeks ago - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 4 months ago - Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma - GlobeNewsWire
- 4 months ago - Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
- 4 months ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 5 months ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 8 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire